Antengene was successfully listed on The Stock Exchange of Hong Kong Limited
Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor) in Mainland China for the Treatment of Myelodysplastic Syndrome
Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL
Approval of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study
IND approval for the TOUCH trial with respect to ATG-010 (selinexor) was received in mainland China
Our licensed rights under the license agreement with Karyopharm were expanded to 17 APAC countries and regions
Our Group completed the Series C financing with an aggregate amount of approximately US$97 million
IND approval for the BUNCH trial with respect to ATG-008 (onatasertib) was received in mainland China
IND approval for the ERASER trial with respect to ATG-017 was received in Australia
Our Drug Discovery Center commenced operation in Shanghai
Our Manufacturing Center commenced operation in Zhejiang Province